Highlights
• AusCann’s joint venture partner, Fundacio´n Daya has worked with the Chilean
National Institute of Public Health to establish a special access scheme similar to that in Australia which now enables immediate access for Chilean patients to medicinal cannabis products.
• The special access scheme allows doctors to prescribe medicinal cannabis to Chilean patients prior to completion of current trials for product registration
Wednesday, 28 March 2018 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (‘AusCann’ or ‘the Company’) is pleased to announce that its Chilean partner, Fundacio´n Daya has worked with the Chilean National Institute of Public Health (ISP) to establish a special access scheme (SAS) which enables patients in Chile access to the first locally produced medicinal cannabis product. A similar access scheme is used in Australia, which enables doctors to prescribe cannabinoid medicines prior to product registration.
For further information please download PDF attached:
Download this document
